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Background
Revealing novel cancer targeting biomarkers is a great
challenge, and especially urging in cancer types with a
more pronounced metastatic feature. We focus on poten-
tial anti-tumor immune reactions of the host. In order to
harness the natural humoral immune response a novel
immunological and molecular genetic panel assay has
been developed for the investigation of patients with
melanomas.
Materials and methods
Punch biopsies were taken of surgically removed fresh
cancerous tissues and peripheral blood was gathered
from the patients involved into the study (n= 125). Ethi-
cal permission was provided by the Scientific and
Research Ethics Committee of the Medical Research
Council of the Hungarian Ministry of Health (ETT
TUKEB 16462- 02/2010). We established and standar-
dized two experimental strategies (Epstein Barr virus
transformation and cloning with limiting dilution assay
(LDA) and tumor infiltrating B cell (TIL-B) antibody
phage display technology) and started basic processes for
a detailed immunglobulin repertoire analysis at DNA
level. We set up a novel native tumor cell membrane pre-
paration technique extremely useful for specific detection
of tumor reacting antibodies or antibody fragments (eg:
immunoblotting, scFv phagemid ELISA). Defining
essential tumor-associated antigens on the cancerous tis-
sue specimen by immunohistochemistry became the
other part of the tumorimmunological panel assay.
Results: We claim that this complex quantitative and
qualitative analysis of antibodies in sera and in the tumor
microenvironment results in revealing tumorspecific
antibodies of human origin. Our antibody profile analysis
revealed glycoprotein and sialylated glycolipid based
tumor-associated antigen-specific antibody-variable
regions in various patterns.
Conclusions
The present technological developments enable the speci-
fic detection of cancer associated sialylated glycolipid and
glycoprotein antigens with unique characteristics. The
study helps to understand the question of “abnormal gly-
cosilation” and its role in cancer. We conclude that the
complex tumorimmunological assay has important poten-
tials in evaluating the host’s anti tumor immune status.
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